BCAS4 Gene: Potential Breast Cancer Drug Target Or Biomarker (G55653)

Target Name: BCAS4

NCBI ID: G55653

BCAS4

BCAS4 Gene: Potential Breast Cancer Drug Target Or Biomarker

Breast carcinoma amplified sequence 4 (BCAS4) is a gene that has been identified as a potential drug target or biomarker for breast cancer. It is a non-coding RNA molecule that has been shown to be highly amplified in the brains of women with breast cancer.

The BCAS4 gene was first identified in 2012 by researchers at the Broad Institute of MIT and Harvard, who used next-generation sequencing to analyze the genomes of women with breast cancer. They found that the BCAS4 gene was significantly more commonly amplified in the brains of women with breast cancer than in the surrounding tissue.

Since then, researchers have been working to understand the role of the BCAS4 gene in breast cancer. They have found that women with breast cancer who have the BCAS4 gene are more likely to have a more aggressive form of the disease, and that treatment with anti-cancer drugs may be less effective in these cases.

In addition, researchers have also found that the BCAS4 gene is expressed in the brains of women with breast cancer, and that these brains may be a source of the cancer cells. This suggests that targeting the BCAS4 gene may be a promising strategy for treating breast cancer.

One potential way to target the BCAS4 gene is through the use of small molecules, such as drugs that can inhibit the activity of the gene. Researchers have been working to develop these small molecules, and have shown that some of them are able to inhibit the growth of cancer cells that express the BCAS4 gene.

Another potential approach to targeting the BCAS4 gene is through the use of antibodies, which are proteins that can specifically bind to the gene and prevent it from being expressed. Researchers have been working to develop these antibodies, and have shown that some of them are able to effectively target the BCAS4 gene in cancer cells.

In addition to these direct approaches, researchers are also exploring the potential of targeting the BCAS4 gene through changes to the balance of cells in the body. For example, they are working to find ways to reduce the number of cells that express the BCAS4 gene, or to stimulate the body's immune system to destroy these cells.

Overall, the BCAS4 gene has the potential to be a valuable drug target or biomarker for breast cancer. Further research is needed to fully understand its role and to develop effective treatments.

Protein Name: Breast Carcinoma Amplified Sequence 4

The "BCAS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCAS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets